Product nameAnti-BIN1 antibody
See all BIN1 primary antibodies
DescriptionRabbit polyclonal to BIN1
Tested applicationsSuitable for: WB, IP, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human BIN1 aa 543-593. The exact sequence is proprietary.
Database link: O00499
- IHC-P: Human ovarian carcinoma tissue. WB: HeLa, HEK-293T and Jurkat whole cell lysate. IP: HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab264303 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2500. Predicted molecular weight: 65 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
|IHC-P||1/500 - 1/2000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
FunctionMay be involved in regulation of synaptic vesicle endocytosis. May act as a tumor suppressor and inhibits malignant cell transformation.
Tissue specificityUbiquitous. Highest expression in the brain and muscle. Isoform IIA is expressed only in the brain where it is concentrated in axon initial segments and nodes of Ranvier. Isoform BIN1 is widely expressed with highest expression in skeletal muscle.
Involvement in diseaseDefects in BIN1 are the cause of centronuclear myopathy autosomal recessive (ARCNM) [MIM:255200]; also known as autosomal recessive myotubular myopathy. Centronuclear myopathies are congenital muscle disorders characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.
Sequence similaritiesContains 1 BAR domain.
Contains 1 SH3 domain.
modificationsPhosphorylated by protein kinase C.
Cellular localizationCytoplasm and Nucleus.
- Information by UniProt
- AMPH 2 antibody
- AMPH2 antibody
- Amphiphysin 2 antibody
Immunohistochemical analysis of formalin-fixed, paraffin-embedded human ovarian carcinoma tissue labeling BIN1 with ab264303 at 1/1,000 dilution. Detection: DAB.
All lanes : Anti-BIN1 antibody (ab264303) at 1 µg/ml
Lane 1 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 3 : Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate
Lysates/proteins at 50 µg per lane.
All lanes : Goat anti-Rabbit Light Chain HRP Conjugate
Predicted band size: 65 kDa
Exposure time: 3 minutes
BIN1 was immunoprecipitated from 1mg of HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate with ab264303 at 6 µg per reaction. Western blot was performed from the immunoprecipitate using ab264303 at 1 µg/ml.
Lane 1: ab264303 IP in HeLa whole cell lysate.
Lane 2: Control IgG.
Exposure time: 3 mins.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab264303 has not yet been referenced specifically in any publications.